Latest revenue
—
as of 2025-12-31
Latest net income
$-5.2M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think APTN is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for APTN.
5-year trend
What this company does
ITEM 1. BUSINESS. Our Company The Company’s objective is to develop and commercialize products utilizing novel technology that enhances the delivery of drugs and other compounds to the brain and other tissues for a variety of indications. Our novel technology was originally developed by researchers in the Department of Neurosurgery at Duke University and licensed by us in 2023. Our website address is www.adaptinbio.com and we can be contacted at info@adaptinbio.com. Information contained on, or that can be accessed through, our website is not a part of this Report. We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, and, for as long…
AI summary unavailable — showing raw filing excerpt
Generated from APTN's filing dated 2026-04-01
Key risks
ITEM 1A. RISK FACTORS. As a smaller reporting company as defined in Item 10 of Regulation S-K (17 CFR § 229.10(f)(1), we are not required to include risk factors in this Report.
AI summary unavailable — showing raw filing excerpt
Generated from APTN's filing dated 2026-04-01
Profitability
Return on equity
347.0%
69.5%Return on assets
-834.6%
96.6%Leverage
Debt / equity
-1.42×
35.3%Debt / assets
340.6%
85.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-1.1M | -90.0% | — |
Q4 2025 2025-12-31 | — | — | $-1.4M | +54.4% | — |
Q3 2025 2025-09-30 | — | — | $-1.7M | -5551.1% | — |
Q2 2025 2025-06-30 | — | — | $-1.5M | -4172.5% | — |
Q1 2025 2025-03-31 | — | — | $-603.1K | -954.8% | — |
Q4 2024 2024-12-31 | — | — | $-3.0M | — | — |
Q3 2024 2024-09-30 | — | — | $-29.7K | +30.9% | — |
Q2 2024 2024-06-30 | — | — | $-35.6K | -737.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on APTN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns APTN
No institutional holdings on file for APTN yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once APTN's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.